All In Biotech

Drug Trial Radar · NCT00606502

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment

Last checked: Nov 20, 2026Latest source record: Mar 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Jan 2008

Primary completion

Jun 24, 2010

Study completion Jun 24, 2010

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Feb 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • PralatrexateDrug

    Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications. Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

  • ErlotinibDrug

    150 mg orally in tablet form Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met.

  • Vitamin B12Dietary supplement

    1 mg intramuscular injection Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment.

  • Folic AcidDietary supplement

    1-1.25 mg orally Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) of Patients Receiving Pralatrexate vs. ErlotinibTime frame: Assessed from date of randomization no less frequently than every 16 weeks for up to 2 years after randomization.

Locations

47 sites in 6 countries. Site status is shown where the registry gives one.

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • Sharp Memorial Hospital

    San Diego, California

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Donald Berdeaux

    Great Falls, Montana

  • Summit Medical Group

    Berkeley Heights, New Jersey

  • Hematology and Oncology Associates South Jersey

    Mount Holly, New Jersey

  • New York Oncology Hematology-Oncology Associates, P.C.

    Latham, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • New Bern Cancer Care

    New Bern, North Carolina

  • Signal Point Clinical Research Center

    Middletown, Ohio

  • Baptist Regional Cancer Center

    Knoxville, Tennessee

  • Cancer Therapy and Research Center

    San Antonio, Texas

  • Providence Everett Medical Center

    Everett, Washington

  • Hospital Britanico

    Capital Federal, Argentina

  • Centro Oncologico Rosario

    Rosario, Argentina

  • CAIPO (Centero Para la Atencion Integral del Paciente Oncologico)

    San Miguel de Tucumán, Argentina

  • ISIS Clinica Especializada

    Santa Fe, Argentina

  • Policlinica Privada - Instituto de Medicina Nuclear

    Bahía Blanca, Buenos Aires, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Cuidad de Buenos Aires, Argentina

  • Biocancer S.A.

    Belo Horizonte, Brazil

  • Instituto do Cancer - Arnaldo Vieira de Carvalho

    São Paulo, Brazil

  • Associação Hospital de Caridade de Ijuí

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinionco - Clínica de Oncologia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação Pio XII - Hospital do Câncer de Barretos

    Barretos, São Paulo, Brazil

  • Masarykuv onkologicky ustav

    Brno, Czechia

  • Palacký University Medical School and Teaching Hospital

    Olomouc, Czechia

  • Vitkovicka nemocnice, a. s.

    Ostrava, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Nemocnice Na Homolce

    Prague, Czechia

  • Fakultni nemocnice na Bulovce

    Prague, Czechia

  • Matrai Allami Gyogyintezet

    Mátraháza, Hungary

  • Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza

    Tatabánya, Hungary

  • National Koranyi TBC and Pulmonology Institute

    Budapest, Pest County, Hungary

  • Jósa András Teaching Hospital

    Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

  • Vas County Markusovszky Hospital

    Szombathely, Vas County, Hungary

  • Zala County Hospital

    Zalaegerszeg, Zala County, Hungary

  • Dharmashila Cancer Hospital & Research Centre

    New Delhi, India

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.